Rhythm Pharmaceuticals, Inc. or Soleno Therapeutics, Inc.: Who Invests More in Innovation?

Biotech Giants: Who Leads in R&D Investment?

__timestampRhythm Pharmaceuticals, Inc.Soleno Therapeutics, Inc.
Wednesday, January 1, 201452800002242216
Thursday, January 1, 201571480004536244
Friday, January 1, 2016195940005184803
Sunday, January 1, 2017228940003068742
Monday, January 1, 2018503370007178000
Tuesday, January 1, 201910945000016267000
Wednesday, January 1, 20209045000023191000
Friday, January 1, 202110412800021453000
Saturday, January 1, 202210863000015265000
Sunday, January 1, 202313495100025189000
Loading chart...

Data in motion

Investing in Innovation: A Tale of Two Biotech Companies

In the competitive world of biotechnology, innovation is the lifeblood of success. Over the past decade, Rhythm Pharmaceuticals, Inc. and Soleno Therapeutics, Inc. have been at the forefront of this race, each investing significantly in research and development (R&D). From 2014 to 2023, Rhythm Pharmaceuticals consistently outpaced Soleno Therapeutics, with R&D expenses growing by an impressive 2,455% compared to Soleno's 1,024% increase. By 2023, Rhythm Pharmaceuticals allocated nearly 84% more to R&D than Soleno, highlighting its commitment to pioneering new treatments. This trend underscores the strategic importance of R&D in driving innovation and maintaining a competitive edge in the biotech industry. As these companies continue to push the boundaries of medical science, their investments in innovation will likely shape the future of healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025